Market Overview

UPDATE: Biogen Idec Posts Downbeat Q4 Profit, Issues Weak 2013 Profit Forecast

Share:
Related BIIB
After Merck Stops Study, What Remains Of The Alzheimer's Drug Pipeline?
Couldn't Make It To Leerink's Global Healthcare Conference? Here Are The Highlights From Day One
Tracking Jeffrey Ubben's ValueAct Portfolio - Q4 2016 Update (Seeking Alpha)

Biogen Idec (NASDAQ: BIIB) reported a 2.7% drop in its fourth-quarter earnings.

Biogen expects 2013 adjusted earnings of $7.15 to $7.25 per share on around 10% rise in revenue. However, analysts were expecting a profit of $7.27 per share on 9% revenue growth.

Biogen's quarterly profit fell to $292.1 million, or $1.23 per share, from $300.2 million, or $1.22 per share, in the year-ago period. Excluding one-time items, it earned $1.40 per share.

Its revenue rose 6.9% to $1.42 billion. However, analysts expected earnings of $1.46 per share on revenue of $1.39 billion.

Biogen shares closed at $146.20 on Friday.

Posted-In: profitEarnings News Guidance

 

Related Articles (BIIB)

View Comments and Join the Discussion!